Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2017

Publisher Name :
Date: 11-Jul-2017
No. of pages: 101

According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2017'; Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

The report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2017' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 5, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Solid Tumor, Melanoma, Metastatic Breast Cancer, Lung Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Ovarian Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Tumor, Endometrial Cancer, Epithelial Tumor, Ewing Sarcoma, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Tumor, Peritoneal Tumor, Skin Cancer, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

  • The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Overview
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Celldex Therapeutics Inc
Daiichi Sankyo Company Ltd
Etubics Corp
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Hummingbird Bioscience Pte Ltd
ImmunoGen Inc
MediaPharma Srl
Merrimack Pharmaceuticals Inc
Merus NV
Novartis AG
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sorrento Therapeutics Inc
Symphogen A/S
Takis Srl
XuanZhu Pharma Co Ltd
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles
AV-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-0702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-3379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elgemtumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCN-411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2849330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
huHER3-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
istiratumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lumretuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCLA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPEV-201959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patritumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poziotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seribantumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-203
Apr 03, 2017: Hummingbird Bioscience presents update on HMBD-001 at AACR in Washington DC
Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting
Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016
Oct 25, 2016: Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer
Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress
Aug 26, 2016: CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)
Aug 11, 2016: CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer
Jul 06, 2016: FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AstraZeneca Plc, H2 2017
Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Pipeline by Celldex Therapeutics Inc, H2 2017
Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Pipeline by Etubics Corp, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017
Pipeline by ImmunoGen Inc, H2 2017
Pipeline by MediaPharma Srl, H2 2017
Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Pipeline by Merus NV, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2017
Pipeline by Sorrento Therapeutics Inc, H2 2017
Pipeline by Symphogen A/S, H2 2017
Pipeline by Takis Srl, H2 2017
Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Discontinued Products, H2 2017
Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Microfluidics Market Insights, Forecast to 2025
    Published: 13-Dec-2018        Price: US 3900 Onwards        Pages: 144
    Global Microfluidics market size will increase to Million US$ by 2025, from Million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Microfluidics. This report researches the worldwide Microfluidics market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and other regions.......
  • Global and Chinese Cell Surface Markers Identification Industry, 2018 Market Research Report
    Published: 13-Dec-2018        Price: US 3000 Onwards        Pages: 135
    The 'Global and Chinese Cell Surface Markers Identification Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Cell Surface Markers Identification industry with a focus on the Chinese market. The report provides key statistics on the market status of the Cell Surface Markers Identification manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report p......
  • Global Biopreservation Market Size, Status and Forecast 2018-2025
    Published: 13-Dec-2018        Price: US 3900 Onwards        Pages: 96
    In 2017, the global Biopreservation market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. This report focuses on the global Biopreservation status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Biopreservation development in United States, Europe and China. The key players covered in this study - BioLife Solutions Inc. - BioCisi......
  • Global Mycoplasma Testing Market Size, Status and Forecast 2018-2025
    Published: 13-Dec-2018        Price: US 3900 Onwards        Pages: 95
    In 2017, the global Mycoplasma Testing market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. This report focuses on the global Mycoplasma Testing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Mycoplasma Testing development in United States, Europe and China. The key players covered in this study - Thermo Fisher Scientific......
  • Global and Chinese Competent Cells Industry, 2018 Market Research Report
    Published: 13-Dec-2018        Price: US 3000 Onwards        Pages: 144
    The 'Global and Chinese Competent Cells Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Competent Cells industry with a focus on the Chinese market. The report provides key statistics on the market status of the Competent Cells manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its defin......
  • Global and Chinese Transfection Technologies Industry, 2018 Market Research Report
    Published: 13-Dec-2018        Price: US 3000 Onwards        Pages: 145
    The 'Global and Chinese Transfection Technologies Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Transfection Technologies industry with a focus on the Chinese market. The report provides key statistics on the market status of the Transfection Technologies manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of th......
  • Global Gene Synthesis Industry Research Report, Growth Trends and Competitive Analysis 2018-2025
    Published: 13-Dec-2018        Price: US 4900 Onwards        Pages: 144
    This report studies the global Gene Synthesis market status and forecast, categorizes the global Gene Synthesis market size (value) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, Central & South America, and Middle East & Africa. Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Cell Counting Market 2018, Forecast to 2023
    Published: 12-Dec-2018        Price: US 4880 Onwards        Pages: 129
    Cell counting is used for the quantification of cells in life sciences. Cell counting is important for research and serves as one of the major steps in a majority of experiments. It is effectively utilized for maintaining cell cultures. Moreover, another important application of cell counting can be seen in the diagnosis of chronic diseases like cancer. Scope of the Report: This report focuses on the Cell Counting in global market, especially in North America, Europe and As......
  • Global Ion Indicators Market Insights, Forecast to 2025
    Published: 12-Dec-2018        Price: US 4900 Onwards        Pages: 115
    The global Ion Indicators market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The objectives of this study are to define, segment, and project the size of the Ion Indicators market based on company, product type, end user and key regions. This report studies the global market size of Ion Indicators in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs